Earnings Feed
Start Free
ADMA BIOLOGICS, INC.·4

Mar 17, 9:00 PM ET

Grossman Adam S 4

4 · ADMA BIOLOGICS, INC. · Filed Mar 17, 2026

Research Summary

AI-generated summary of this filing

Updated

ADMA (ADMA) CEO Adam Grossman Exercises Options, Sells Shares

What Happened

  • Adam S. Grossman, President, CEO and a director of ADMA Biologics (ADMA), exercised options to acquire 15,000 shares at $5.40 (cost $81,000) and on the same day sold 21,000 shares in open-market transactions at $15.16, producing total sale proceeds of $318,360 (15,000 shares for $227,400 and 6,000 shares for $90,960). The filing also reports a derivative disposition of 15,000 shares reported at $0.00 (related to option/derivative settlement).

Key Details

  • Transaction date: 2026-03-16. Sale price: $15.16 per share. Exercise price paid for acquired shares: $5.40 per share.
  • Total proceeds from sales: $318,360. Cash paid to exercise: $81,000 for 15,000 shares.
  • Reported plan: Transactions were effected under a Rule 10b5‑1 trading plan established Nov 14, 2025 (footnote F1).
  • Beneficial ownership disclosed (per filing footnotes): 1,218,943 shares directly owned by Grossman, plus unvested RSUs totaling 893,834 (282,529 + 189,017 + 278,864 + 143,424) and outstanding option coverage (option granted Feb 26, 2024 with 217,737 shares vesting first-year; full grant equals ~870,948 underlying shares). Some shares are held through entities Areth, LLC and Hariden, LLC (Grossman has control/manager roles).
  • Filing timeliness: Form filed 2026-03-17 reporting 2026-03-16 transactions — no late filing indicated in the record.

Context

  • This is a common pattern where an insider exercises options and sells shares the same day. The combination of an exercise (derivative conversion) and immediate sale is often a sell-to-cover or cashless-style transaction; here it was executed under a pre-established 10b5‑1 plan.
  • Sales do not necessarily signal a change in sentiment; purchases are typically more informative about bullishness. This filing is factual disclosure of insider activity required by SEC rules.

Insider Transaction Report

Form 4
Period: 2026-03-16
ADMA BIOLOGICS, INC.ADMA
Grossman Adam S
DirectorPresident and CEO
Transactions
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-03-16$5.40/sh+15,000$81,000→ 2,133,777 total
  • Sale

    Common Stock

    [F1][F2]
    2026-03-16$15.16/sh−15,000$227,400→ 2,118,777 total
  • Sale

    Common Stock

    [F1][F2][F3][F4][F5]
    2026-03-16$15.16/sh−6,000$90,960→ 2,112,777 total
  • Exercise/Conversion

    Stock Option (right to buy)

    [F1][F8]
    2026-03-16−15,000→ 690,950 total
    Exercise: $5.40Exp: 2034-02-26→ Common Stock (15,000 underlying)
Holdings

  • Common Stock

    [F6]
    (indirect: See Footnote)
    1,143,426

  • Common Stock

    [F7]
    (indirect: See Footnote)
    580,957
Footnotes (8)
  • [F1]Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.
  • [F2]The price reported in Column 4 is the price at which the shares were sold.
  • [F3]Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
  • [F4](continued from footnote 2) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 143,424 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
  • [F5](continued from footnote 3) and (v) 1,218,943 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
  • [F6]These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth.
  • [F7]These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.
  • [F8]The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.
Signature
/s/ Adam S. Grossman, by Michael A. Goldstein as Attorney-in-fact|2026-03-17

Documents

1 file
  • 4
    form4.xmlPrimary

    FROM 4